Erythropoietin (EPO) Biomarkers Market

The Erythropoietin (EPO) biomarkers market is expected to reach USD 1.06 billion by 2030, from USD 0.69 billion in 2025, reporting a CAGR of 9.0% between 2025 and 2030. The growth of the Erythropoietin (EPO) biomarkers market is due to several key factors, including the increasing prevalence of CKD and anemia-related conditions and advancements in biomarker diagnostics and precision medicine.

Key players in the Erythropoietin (EPO) biomarkers industry include Amgen Inc. (US), Biocon Ltd (India), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Pfizer Inc. (US), Siemens Healthineers (Germany), and 3SBio Group (China). Companies in this space are adopting expansion strategies to strengthen their global footprint and advance their technology portfolios.

To know about the assumptions considered for the study download the pdf brochure

In January 2025, Merck KGaA and Diatech Pharmacogenetics partnered to enhance biomarker testing access in the Middle East and Africa, specifically improving RAS biomarker testing and personalized treatment options.

Amgen Inc (US)

Amgen Inc. is a leading participant in the Erythropoietin (EPO) biomarkers landscape, leveraging its deep expertise in biologics and anemia therapeutics to advance biomarker-driven evaluation of EPO response and safety. The company focuses on integrating laboratory biomarkers, pharmacodynamic indicators, and real-world clinical data to support patient stratification, dose optimization, and treatment monitoring in chronic kidney disease and oncology-related anemia. Through its strong clinical development infrastructure and data analytics capabilities, Amgen supports the use of EPO biomarkers across clinical trials and post-marketing surveillance to enable more personalized and evidence-based anemia management.

Biocon (India)

Biocon is an emerging leader in the EPO biomarkers market, particularly within cost-sensitive and high-burden anemia populations. The company emphasizes the development and application of biochemical and hematological biomarkers to demonstrate biosimilar comparability, therapeutic efficacy, and long-term safety of erythropoietin products. By aligning biomarker strategies with regulatory requirements and real-world treatment settings, Biocon enables broader adoption of EPO biomarkers in clinical development, biosimilar validation, and population-level anemia management across emerging markets.

Johnson & Johnson (US)

Johnson & Johnson (J&J) is a key player in the EPO biomarkers market with its focus on advanced diagnostics, data-driven clinical research, and precision medicine platforms. The company combines molecular, clinical, and outcome-based biomarkers to assess the erythropoietin-related treatment outcomes and risk profiles, particularly in complex patients. Through the use of biomarker analysis with digital health solutions and global clinical research infrastructure, J&J makes it possible to integrate EPO biomarkers into clinical practice, treatment monitoring, and value-based care frameworks.

Market Ranking

The Erythropoietin (EPO) biomarkers market is increasingly shaped by large biopharmaceutical companies that integrate therapeutic expertise with advanced biomarker development to support clinical research, regulatory compliance, and real-world clinical adoption. Amgen (US) plays a pivotal role by leveraging its leadership in erythropoiesis-stimulating agents to develop and apply hematological, pharmacodynamic, and clinical biomarkers that enable patient stratification, dose optimization, and treatment response monitoring in chronic kidney disease and oncology-related anemia. Biocon (India) contributes significantly through its strong focus on biosimilars, utilizing validated EPO biomarkers to demonstrate product comparability, efficacy, and long-term safety. The company emphasizes biomarker integration across clinical trials and post-marketing studies, supporting cost-effective anemia management in emerging and high-burden markets. Johnson & Johnson (US) strengthens the EPO biomarkers ecosystem through its global clinical research infrastructure and data-driven healthcare platforms, integrating clinical and outcome-based biomarkers to support therapeutic monitoring and evidence generation across diverse care settings. F. Hoffmann-La Roche Ltd. (Switzerland) advances the market by combining in-vitro diagnostics, assay development, and analytics to standardize EPO biomarker measurement and validation, enabling broader adoption across hospital and laboratory networks. Merck KGaA (Germany) supports the market through life science tools, reagents, and analytical platforms that facilitate EPO biomarker discovery, validation, and deployment across pharmaceutical development and real-world clinical workflows.

Related Reports:

Erythropoietin (EPO) Biomarkers Market by Type (Erythropoietin Alfa, Erythropoietin Zeta), Application (Anemic Disorders, Cancer, End-stage renal disorders), End User (Hospitals, Diagnostic Centers) – Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com